LATEST UPDATES » Vol 22, No 03, March 2018 – Women in Science - Making a difference       » Brain aging in ASEAN       » Chinese scientists find antidote to centipede venom       » Measuring the risks and rewards of drug development       » Ketone drink could help diabetics by lowering blood sugar       » What value-based healthcare means for Asia       » Improve healthcare access to tackle Asia's healthcare challenge      
Indian court's Novartis ruling keeps door to cheap drugs open
The Swiss pharmaceutical company Novartis has lost its seven-year court battle to patent the cancer drug Glivec in India, where generic versions of the medicine provide life-saving drugs to thousands of people.

Novartis wanted exclusive rights to manufacture the drug on the grounds that a new substance had been used in its production. But the Indian Supreme Court in Delhi ruled that the small changes to the drug were not worthy of a patent: the drug had "failed in both the tests of invention and patentability", it said.

The ruling is a victory for Indian generic drug companies and will enable some 300,000 patients in the country and many more in other developing countries to access cheaper generic versions of Glivec.

India is widely known as the 'world's pharmacy', because it supplies cheap, generic versions of medicines to many countries across the developing world.

Prices of Indian generic versions of Glivec, which is mainly used to treat leukaemia, are many times lower than those of the branded drug.

Novartis was contesting the rejection of its 2005 patent application by the Indian Patent Office and the Intellectual Property Appellate Board to patent imatinib, a salt form of imatinib mesylate, the drug marketed as Glivec.

The court ruled that as imatinib is only a modification of a known molecule, and since it does not offer improved therapeutic efficacy, it is not patentable, according to the 2005 Indian Patents Act.

Section 3(d) of the 2005 act stipulates that an innovation constituting "the mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance" cannot be patented.

Generic versions of Glivec are currently marketed by Indian companies like Ranbaxy, Natco Pharma and Cipla.

Natco Pharma, one of the appellants in the Novartis case, says the judgment is a victory for both cancer patients and the Indian government.

Madineedi Adinarayana, Natco's general manager, tells SciDev.Net that the judgment is a victory for the entire generic pharmaceutical industry and for section 3(d) of the patents act.

"It is a feature unique to Indian law, and many countries like China and South Korea plan to amend their laws to incorporate this provision," he says. "We are offering Glivec to Indian patients for 9,600 Indian rupees [US$177] a month while Novartis charges 110,000 rupees [US$2,270] a month."

Adinarayana says the Glivec judgement will ensure that drugs are accessible to the poor.

Leena Menghaney, India manager for Médecins Sans Frontières' Access Campaign, tells SciDev.Net that the ruling "appears to be the best outcome for patients in developing countries as fewer patents will be granted on existing medicines".

"Novartis's attacks on the elements of India's patent law that protect public health have failed," she says.

"The Supreme Court's decision prevents companies from abusing the patent system … [and] confirms that all patent offices in India have to use this interpretation and the law is now clear and must be strictly applied," she adds.

But Novartis has said the judgment will hinder research on new drugs and discourage innovation.

"We strongly believe that original innovation should be recognized in patents to encourage investment in medical innovation especially for unmet medical needs," Ranjit Shahani, vice chairman and managing director of Novartis India, said in a press statement.

M Sreelata
Source: Science Development Network

Click here for the complete issue.

news Shire, Microsoft and EURORDIS form Global Commission to accelerate time to diagnosis for children with rare diseases
news EmTech Asia explores future of life, humanity and economy
news Biology of Ageing II - Impactful Interventions
Asia Pacific Biotech News

Lady Ganga: Nilza'S Story
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2018
Obesity / Outlook for 2018
Searching for the fountain of youth
Women in Science - Making a difference
Digestive health / Intellectual property
Asthma / Dental health
Oncology / Biotech landscape in APAC
Water management / Vaccination
Regenerative medicine / Biotech start ups
Digital healthcare / 3D printing
Bones / Breast cancer
Liver health / Top science research nations & institutions
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
About Us
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy